The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use

Journal of Virological Methods

Volumn 163, Issue 2, 2010, Pages 195-204

  Di Lullo, Giulia ^a   Soprana, Elisa ^a   Panigada, Maddalena ^a,b   Palini, Alessio ^a   Agresti, Alessandra ^a   Comunian, Claudio ^a   Milani, Adelaide ^c   Capua, Ilaria ^c   Erfle, Volker ^d   Siccardi, Antonio G ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS   (Italy)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Flow cytometry sorting cloning; Fluorescent proteins; Marker gene swapping; Recombinant MVA

Indexed keywords

GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; HIGH MOBILITY GROUP B1 PROTEIN; MODIFIED VACCINIA VIRUS ANKARA VACCINE; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL CELL; ARTICLE; CHICKEN; CONTROLLED STUDY; DNA SEQUENCE; DRUG SYNTHESIS; EMBRYO; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC RECOMBINATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFLUENZA VIRUS A H5N1; MARKER GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; TRANSGENE; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS ISOLATION; VIRUS PURIFICATION; VIRUS RECOMBINANT;

ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHICK EMBRYO; CHICKENS; CULTURE MEDIA, SERUM-FREE; FIBROBLASTS; FLOW CYTOMETRY; GENES, VIRAL; GREEN FLUORESCENT PROTEINS; HMGB1 PROTEIN; INFLUENZA A VIRUS, H5N1 SUBTYPE; LUMINESCENT PROTEINS; RATS; RECOMBINATION, GENETIC; SMALLPOX VACCINE; STAINING AND LABELING; VACCINIA VIRUS;

INFLUENZA A VIRUS; MAMMALIA; RATTUS; VACCINIA VIRUS ANKARA;

EID: 73249124560     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.09.016     Document Type: Article

References (32)

1. Agresti A., and Bianchi M.E. HMGB proteins and gene expression. Curr. Opin. Genet. Dev. 13 (2003) 170-178
2. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20 (2002) 1949-1955
3. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 (1998) 365-396
4. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., and Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75 (2001) 5151-5158
5. Bejon P., Ogada E., Mwangi T., Milligan P., Lang T., Fegan G., Gilbert S.C., Peshu N., Marsh K., and Hill A.V. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2 (2007) e707
6. Carroll M.W., and Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238 (1997) 198-211
7. Carroll M.W., Overwijk W.W., Chamberlain R.S., Rosenberg S.A., Moss B., and Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15 (1997) 387-394
8. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23 (1997) 1094-1097
9. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., Goebel F.D., and Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 (2003) 21-29
10. Cottingham M.G., Andersen R.F., Spencer A.J., Saurya S., Furze J., Hill A.V., and Gilbert S.C. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3 (2008) e1638
11. Di Lullo G., Soprana E., Panigada M., Palini A., Erfle V., Staib C., Sutter G., and Siccardi A. Marker gene swapping facilitates recombinant modified vaccinia virus Ankara production by host-range selection. J. Virol. Methods 156 (2009) 37-43
12. Drexler I., Antunes E., Schmitz M., Wolfel T., Huber C., Erfle V., Rieber P., Theobald M., and Sutter G. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 59 (1999) 4955-4963
13. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79 Pt 2 (1998) 347-352
14. Gilbert P.A., Comanita L., Barrett J., Peters A., Szabat M., McFadden G., and Dekaban G.A. Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development. Cytotechnology 48 (2005) 79-88
15. Hiller G., Eibl H., and Weber K. Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release. J. Virol. 39 (1981) 903-913
16. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak Jr. M., Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., and Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70 (1996) 3741-3752
17. Hollinshead M., Rodger G., Van Eijl H., Law M., Hollinshead R., Vaux D.J., and Smith G.L. Vaccinia virus utilizes microtubules for movement to the cell surface. J. Cell Biol. 154 (2001) 389-402
18. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., Bashir F., Bhatt K., Ogutu H., Wakasiaka S., Matu L., Waruingi W., Odada J., Oyaro M., Indangasi J., Ndinya-Achola J., Konde C., Mugisha E., Fast P., Schmidt C., Gilmour J., Tarragona T., Smith C., Barin B., Dally L., Johnson B., Muluubya A., Nielsen L., Hayes P., Boaz M., Hughes P., Hanke T., McMichael A., Bwayo J., and Kaleebu P. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26 (2008) 2788-2795
19. Kato N., Eggers H.J., and Rolly H. Inhibition of release of vaccinia virus by N1-isonicotinoly-N2-3-methyl-4-chlorobenzoylhydrazine. J. Exp. Med. 129 (1969) 795-808
20. Mayr A., and Danner K. Significance of animal pox for man following elimination of compulsory vaccination against smallpox. Berl. Munch. Tierarztl. Wochenschr. 92 (1979) 251-256
21. Mayr A., Hochstein-Mintzel V., and Stickl H. Abstammung Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3 (1975) 6-14
22. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
23. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 Pt 5 (1991) 1031-1038
24. Payne L.G., and Kristensson K. The effect of cytochalasin D and monensin on enveloped vaccinia virus release. Arch. Virol. 74 (1982) 11-20
25. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74 (2000) 7651-7655
26. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., and Hill A.V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4 (1998) 397-402
27. Staib C., Drexler I., Ohlmann M., Wintersperger S., Erfle V., and Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28 (2000) p. 1137-1142, 1144-1146, 1148
28. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10847-10851
29. Sutter G., Ramsey-Ewing A., Rosales R., and Moss B. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol. 68 (1994) 4109-4116
30. Urbonaviciute V., Furnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., Bianchi M.E., Kirschning C., Wagner H., Manfredi A.A., Kalden J.R., Schett G., Rovere-Querini P., Herrmann M., and Voll R.E. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205 (2008) 3007-3018
31. Weidinger G., Ohlmann M., Schlereth B., Sutter G., and Niewiesk S. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 19 (2001) 2764-2768
32. Wyatt L.S., Shors S.T., Murphy B.R., and Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14 (1996) 1451-1458